tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - agenti antineoplastici - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocitica, cronica, b-cell - agenti antineoplastici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
luxazone
abbvie s.r.l. - desametasone - desametasone
ethrane
abbvie s.r.l. - idrocarburi alogenati - idrocarburi alogenati
clarvisan pva
abbvie s.r.l. - altri oftalmologici - altri oftalmologici
vistagan
abbvie s.r.l. - levobunololo - levobunololo
calcijex
abbvie s.r.l. - calcitriolo - calcitriolo
alphagan
abbvie s.r.l. - brimonidina - brimonidina
lacrilube
abbvie s.r.l. - lacrime artificiali e altri preparati indifferenti - lacrime artificiali e altri preparati indifferenti